Insulet (PODD) AI Stock Analysis

• Market Cap: $22.59B
• Dividend Yield: N/A
• Average Volume (3M): 582.61K
• Price to Earnings (P/E): 97.7
• Beta (1Y): 1.01
• Revenue Growth: 25.99%
• EPS Growth: -40.46%
• Country: US
• Employees: 3,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 1.17
• Shares Outstanding: 70,392,530
• 10 Day Avg. Volume: 414,792
• 30 Day Avg. Volume: 582,606
• PEG Ratio: 0.43
• Price to Book (P/B): 15.10
• Price to Sales (P/S): 8.83
• P/FCF Ratio: 59.90
• Enterprise Value/Market Cap: 1.00
• Enterprise Value/Revenue: 9.53
• Enterprise Value/Gross Profit: 13.47
• Enterprise Value/Ebitda: 55.23
• 1Y Price Target: $368.43
• Price Target Upside: 13.08% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 18

• Rating: 74 Outperform
• Price Target: $354.00 ▲(8.66% Upside)

Insulet Corporation's overall stock score is driven by its strong financial performance and positive earnings call sentiment, highlighting robust revenue growth and market expansion. However, the high P/E ratio suggests overvaluation, and technical indicators show mixed signals, contributing to a moderate overall score.

Positive Factors

Revenue Growth

The significant revenue growth, especially surpassing $600 million for the first time, indicates strong market demand and effective business strategies, supporting long-term financial health.

International Expansion

Strong international revenue growth reflects successful global expansion efforts, enhancing market presence and diversifying revenue streams, which is crucial for sustained growth.

Product Innovation

Innovations in the Omnipod 5 system improve clinical outcomes, strengthening competitive advantage and potentially increasing market share in diabetes management.

Negative Factors

Net Profit Margin Decline

A declining net profit margin indicates potential challenges in maintaining profitability, which could affect long-term financial stability if not addressed.

Inventory-Related Charges

Inventory-related charges suggest inefficiencies in inventory management, which could impact cost structures and profitability if persistent.

Potential Medicare Impact

Potential changes in Medicare regulations could affect product reimbursement rates, posing a risk to revenue and market dynamics in the healthcare sector.

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation is a medical device company that specializes in the development and manufacturing of innovative insulin delivery systems, primarily for people with diabetes. The company is best known for its Omnipod Insulin Management System, which offers a tubeless, wearable insulin pump designed to improve the quality of life for individuals managing diabetes. Insulet operates in the healthcare sector, focusing on diabetes management and has expanded its product offerings to include advanced technology that integrates with continuous glucose monitoring systems.

How the Company Makes Money

Insulet generates revenue primarily through the sale of its Omnipod Insulin Management Systems and the related consumable products, such as insulin cartridges and infusion sets. The company has a subscription-based model for the consumables, which provides a recurring revenue stream as patients require ongoing supplies for their insulin delivery. Additionally, partnerships with healthcare providers and payers enhance its revenue model, as Insulet collaborates with insurance companies to ensure coverage for its products, thereby increasing accessibility for users. The company also invests in research and development to enhance its products, potentially leading to new revenue opportunities through innovation and improved technology integration with diabetes management solutions.

Insulet Financial Statement Overview

Summary

Insulet's financial performance is robust, with strong revenue growth and profitability metrics. The company has improved its leverage position and continues to generate healthy cash flows. While there is a slight decline in net profit margin, the overall financial health remains strong, positioning the company well in the medical devices industry.

Income Statement

Insulet has demonstrated strong revenue growth with a 7.3% increase in TTM, supported by a robust gross profit margin of 70.7%. The net profit margin has slightly decreased to 10% from the previous annual report's 20.2%, indicating some pressure on profitability. However, the EBIT and EBITDA margins remain healthy, reflecting efficient operations.

Balance Sheet

The company's debt-to-equity ratio has improved to 0.96 in TTM, showing reduced leverage compared to previous periods. Return on equity is strong at 18.4%, indicating effective use of equity to generate profits. The equity ratio stands at 42.2%, suggesting a balanced capital structure with a solid equity base.

Cash Flow

Insulet's free cash flow growth is impressive at 35% in TTM, indicating strong cash generation capabilities. The operating cash flow to net income ratio is 0.50, showing moderate cash conversion efficiency. The free cash flow to net income ratio of 0.78 suggests a healthy cash flow relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.36B	2.07B	1.70B	1.31B	1.10B	904.40M
Gross Profit	1.67B	1.45B	1.16B	805.60M	752.10M	582.30M
EBITDA	407.30M	423.70M	323.60M	109.00M	139.60M	110.30M
Net Income	236.10M	418.30M	206.30M	4.60M	16.80M	6.80M
Balance Sheet
Total Assets	3.47B	3.09B	2.59B	2.25B	2.05B	1.87B
Cash, Cash Equivalents and Short-Term Investments	1.12B	953.40M	704.20M	674.70M	791.60M	947.60M
Total Debt	1.42B	1.42B	1.45B	1.43B	1.29B	1.08B
Total Liabilities	2.01B	1.88B	1.86B	1.77B	1.49B	1.27B
Stockholders Equity	1.46B	1.21B	732.70M	476.40M	556.30M	603.60M
Cash Flow
Free Cash Flow	388.30M	305.40M	70.10M	-38.30M	-190.80M	-82.50M
Operating Cash Flow	506.50M	430.30M	145.70M	119.00M	-68.10M	84.00M
Investing Cash Flow	-136.20M	-146.20M	-119.40M	-191.10M	-82.70M	14.00M
Financing Cash Flow	-78.90M	-28.10M	-13.60M	-40.30M	40.70M	605.50M

Insulet Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 325.80
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Positive. The current price of 325.8 is above the 20-day moving average (MA) of 317.35, below the 50-day MA of 327.32, and above the 200-day MA of 294.47, indicating a neutral trend. The MACD of 0.58 indicates Negative momentum. The RSI at 54.21 is Neutral, neither overbought nor oversold. The STOCH value of 48.86 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PODD.

Insulet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STE	―	$23.71B	36.50	9.73%	0.97%	2.47%	63.68%
ZBH	―	$20.41B	25.09	6.52%	0.93%	4.11%	-14.43%
PODD	―	$22.59B	97.66	19.18%	―	25.99%	-40.46%
DXCM	―	$27.58B	49.45	22.83%	―	9.30%	-14.95%
PHG	―	$27.61B	-35.39	―	3.07%	-0.76%	-55.03%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TNDM	―	$1.01B	―	-111.91%	―	25.84%	-47.67%

Insulet Corporate Events

Insulet Appoints New CFO Amid Revenue Growth

On September 16, 2025, Insulet Corporation announced the appointment of Flavia Pease as the new Chief Financial Officer, succeeding Ana Maria Chadwick. This transition is expected to ensure continued financial stability and growth, as Pease brings extensive experience from her previous roles at Charles River Laboratories and Johnson & Johnson. Additionally, Insulet anticipates exceeding its third-quarter 2025 revenue growth guidance, driven by strong new customer starts in both U.S. and international markets, which reflects positively on its market performance and future outlook.

The most recent analyst rating on (PODD) stock is a Buy with a $365.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Corporation Reports Strong Q2 2025 Growth

Insulet Corporation, based in Massachusetts, is a leading medical device company specializing in tubeless insulin pump technology through its Omnipod product platform, offering innovative solutions for diabetes management.

Insulet’s Earnings Call Highlights Robust Growth and Optimism

Insulet Corporation’s recent earnings call conveyed a predominantly positive sentiment, underscored by remarkable revenue growth and successful international expansion. The company demonstrated confidence in its future by raising its full-year guidance, despite facing some financial challenges such as inventory-related charges and increased interest expenses. Overall, the positive developments significantly outweighed the negatives, painting a promising picture for Insulet’s future.